Загрузка...
Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients
Background: Tocilizumab (TCZ), a monoclonal antibody against the most prevalent cytokine interleukin-6 (IL-6), is an emerging therapeutic option for COVID-19 infections. The present study was undertaken to assess the therapeutic response of TCZ therapy in severely or critically ill COVID-19 patients...
Сохранить в:
| Опубликовано в: : | Indian J Crit Care Med |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Jaypee Brothers Medical Publishers
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7991771/ https://ncbi.nlm.nih.gov/pubmed/33790504 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5005/jp-journals-10071-23747 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|